



Short Review



RIFM fragrance ingredient safety assessment, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-, CAS Registry Number 862079-91-2

A.M. Api^a, D. Belsito^b, D. Botelho^a, M. Bruze^c, G.A. Burton Jr.^d, M.A. Cancelleri^a, H. Chon^a, M.L. Dagli^e, W. Dekant^f, C. Deodhar^a, A.D. Fryer^g, L. Jones^a, K. Joshi^a, A. Lapczynski^a, M. Lavelle^a, I. Lee^a, D.C. Liebler^h, H. Moustakas^a, J. Muldoon^a, T.M. Penningⁱ, G. Ritacco^a, N. Sadekar^a, T.W. Schultz^j, D. Selechnik^a, F. Siddiqi^a, I.G. Sipes^k, G. Sullivan^{a,*}, Y. Thakkar^a, Y. Tokura^l

^a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

^b Member Expert Panel for Fragrance Safety, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

^c Member Expert Panel for Fragrance Safety, Malmö University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmö, SE-20502, Sweden

^d Member Expert Panel for Fragrance Safety, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 48109, USA

^e Member Expert Panel for Fragrance Safety, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. Dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

^f Member Expert Panel for Fragrance Safety, University of Würzburg, Department of Toxicology, Versbacher Str. 9, 97078, Würzburg, Germany

^g Member Expert Panel for Fragrance Safety, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

^h Member Expert Panel for Fragrance Safety, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

ⁱ Member of Expert Panel for Fragrance Safety, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

^j Member Expert Panel for Fragrance Safety, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN, 37996-4500, USA

^k Member Expert Panel for Fragrance Safety, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA

^l Member Expert Panel for Fragrance Safety, The Journal of Dermatological Science (JDS), Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

ARTICLE INFO

Handling Editor: Dr. Bryan Delaney

* Corresponding author.

E-mail address: gsullivan@rifm.org (G. Sullivan).

<https://doi.org/10.1016/j.fct.2023.114304>


Received 2 October 2023; Accepted 27 November 2023

Available online 4 December 2023

0278-6915/© 2023 Elsevier Ltd. All rights reserved.

Version: 092823. Initial publication. All fragrance materials are evaluated on a five-year rotating basis. Revised safety assessments are published if new relevant data become available. Open access to all RIFM Fragrance Ingredient Safety Assessments is here: [france-science-and-technology.elsevier.com](https://www.sciencedirect.com/journal/france-science-and-technology).

Name: Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-CAS Registry Number: 862079-91-2



Abbreviation/Definition List:

2-Box Model - A RIFM, Inc. proprietary *in silico* tool used to calculate fragrance air exposure concentration

AF - Assessment Factor

BCF - Bioconcentration Factor

CNIH - Confirmation of No Induction in Humans test. A human repeat insult patch test that is performed to confirm an already determined safe use level for fragrance ingredients (Na et al., 2021)

Creme RIFM Model - The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015; Safford et al., 2017) compared to a deterministic aggregate approach

DEREK - Derek Nexus is an *in silico* tool used to identify structural alerts

DRF - Dose Range Finding

DST - Dermal Sensitization Threshold

ECHA - European Chemicals Agency

ECOSAR - Ecological Structure-Activity Relationships Predictive Model

EU - Europe/European Union

GLP - Good Laboratory Practice

IFRA - The International Fragrance Association

LOEL - Lowest Observed Effect Level

MOE - Margin of Exposure

MPPD - Multiple-Path Particle Dosimetry. An *in silico* model for inhaled vapors used to simulate fragrance lung deposition

NA - North America

NESIL - No Expected Sensitization Induction Level

NOAEC - No Observed Adverse Effect Concentration

NOAEL - No Observed Adverse Effect Level

NOEC - No Observed Effect Concentration

NOEL - No Observed Effect Level

OECD - Organisation for Economic Co-operation and Development

OECD TG - Organisation for Economic Co-operation and Development Testing Guidelines

PBT - Persistent, Bioaccumulative, and Toxic

PEC/PNEC - Predicted Environmental Concentration/Predicted No Effect Concentration

Perfumery - In this safety assessment, perfumery refers to fragrances made by a perfumer used in consumer products only. The exposures reported in the safety assessment include consumer product use but do not include occupational exposures.

QRA - Quantitative Risk Assessment

QSAR - Quantitative Structure-Activity Relationship

REACH - Registration, Evaluation, Authorisation, and Restriction of Chemicals

RfD - Reference Dose

RIFM - Research Institute for Fragrance Materials

RQ - Risk Quotient

Statistically Significant - Statistically significant difference in reported results as compared to controls with a $p < 0.05$ using appropriate statistical test

TTC - Threshold of Toxicological Concern

UV/Vis spectra - Ultraviolet/Visible spectra

VCF - Volatile Compounds in Food

VoU - Volume of Use

vPvB - (very) Persistent, (very) Bioaccumulative

WoE - Weight of Evidence

The Expert Panel for Fragrance Safety* concludes that this material is safe as described in this safety assessment.

This safety assessment is based on the RIFM Criteria Document (Api et al., 2015), which should be referred to for clarifications.

Each endpoint discussed in this safety assessment includes the relevant data that

(continued on next column)

(continued)

were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM Database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

Summary: The existing information supports the use of this material as described in this safety assessment.

Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data show that pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is not genotoxic. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the Threshold of Toxicological Concern (TTC) for a Cramer Class III material, and the exposure to pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is below the TTC (0.0015 mg/kg/day, 0.0015 mg/kg/day, and 0.47 mg/day, respectively). The skin sensitization endpoint was completed using the Dermal Sensitization Threshold (DST) for reactive materials (64 $\mu\text{g}/\text{cm}^2$); exposure is below the DST. The photoirritation/photoallergenicity endpoints were evaluated based on ultraviolet/visible (UV/Vis) spectra for read-across analog pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7); pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is not expected to be photoirritating/photoallergenic. The environmental endpoints were evaluated; pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use (VoU) in Europe and North America (i.e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are <1.

Human Health Safety Assessment

Genotoxicity: Not genotoxic. (RIFM, 2017; RIFM, 2018)

Repeated Dose Toxicity: No NOAEL available. Exposure is below TTC.

Reproductive Toxicity: No NOAEL available. Exposure is below TTC.

Skin Sensitization: Not a concern for skin sensitization under the declared use levels; exposure is below the DST.

Photoirritation/Photoallergenicity: Not expected to be photoirritating/photoallergenic. (UV/Vis Spectra, RIFM Database)

Local Respiratory Toxicity: No NOAEL available. Exposure is below the TTC.

Environmental Safety Assessment

Hazard Assessment:

Persistence: Screening-level: 2.29 (BIOWIN 3) (EPI Suite v4.11; US EPA, 2012a)

Bioaccumulation: Screening-level: 138.3 L/kg (EPI Suite v4.11; US EPA, 2012a)

Ecotoxicity: Screening-level: Fish LC50: 7.50 mg/L (RIFM Framework; Salvito et al., 2002)

Conclusion: Not PBT or vPvB as per IFRA Environmental Standards

Risk Assessment:

Screening-level: PEC/PNEC (North America and Europe) < 1 (RIFM Framework; Salvito et al., 2002)

Critical Ecotoxicity Endpoint: Fish LC50: 7.50 mg/L (RIFM Framework; Salvito et al., 2002)

RIFM PNEC is: 0.00750 $\mu\text{g}/\text{L}$

• **Revised PEC/PNECs (2019 IFRA VoU):** North America and Europe: not applicable; cleared at screening-level

1. Identification

- Chemical Name:** Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-
- CAS Registry Number:** 862079-91-2
- Synonyms:** Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-
- Molecular Formula:** $\text{C}_{13}\text{H}_{15}\text{N}$

5. **Molecular Weight:** 185.27 g/mol
6. **RIFM Number:** 7115
7. **Stereochemistry:** Three stereocenters and 8 possible stereoisomers

2. Physical data

1. **Boiling Point:** 268.40 °C (EPI Suite)
2. **Flash Point:** Not Available
3. **Log K_{ow}:** 3.75
4. **Melting Point:** 66.65 °C (EPI Suite)
5. **Water Solubility:** 6.50 + E02 mg/L at 25 °C (WSKOW v1.42 in EPI Suite)
6. **Specific Gravity:** Not Available
7. **Vapor Pressure:** 5.57E-01 Pa at 25 °C, (EPI Suite)
8. **UV Spectra:** Not available
9. **Appearance/Organoleptic:** Not available

3. Volume of use (worldwide band)

1. <0.1 metric ton per year (IFRA, 2019)

4. Exposure to fragrance ingredient (Creme RIFM aggregate exposure model v3.2.6)

1. **95th Percentile Concentration in Fine Fragrance:** 0.02% (RIFM, 2021)
2. **Inhalation Exposure*:** 0.000025 mg/kg/day or 0.0017 mg/day (RIFM, 2021)
3. **Total Systemic Exposure**:** 0.00015 mg/kg/day (RIFM, 2021)

*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM Aggregate Exposure Model (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey, 2017).

**95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section V. It is derived from concentration survey data in the Creme RIFM Aggregate Exposure Model and includes exposure via dermal, oral, and inhalation routes whenever the fragrance ingredient is used in products that include these routes of exposure (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey, 2017).

5. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

6. Computational toxicology evaluation

1. Cramer Classification: Class III, High

Expert Judgment	Toxtree v3.1	OECD QSAR Toolbox v4.5
III	III	III

2. Analogs Selected:

- a. **Genotoxicity:** None
- b. **Repeated Dose Toxicity:** None
- c. **Reproductive Toxicity:** None
- d. **Skin Sensitization:** None
- e. **Photoirritation/Photoallergenicity:** Pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7)
- f. **Local Respiratory Toxicity:** None
- g. **Environmental Toxicity:** None

3. Read-across Justification:

 See Appendix below

7. Metabolism

No relevant data available for inclusion in this safety assessment.

Additional References:

None

8. Natural occurrence

Pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is not reported to occur in foods by the VCF*.

*VCF (Volatile Compounds in Food): Database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that have been found in natural (processed) food products. Includes FEMA GRAS and EU-Flavis data.

9. REACH dossier

Pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- has not been pre-registered; no dossier available as of 09/27/23.

10. Conclusion

The existing information supports the use of this material as described in this safety assessment.

11. Summary

11.1. Human health endpoint summaries

11.1.1. Genotoxicity

Based on the current existing data, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- does not present a concern for genotoxicity.

11.1.1.1. Risk assessment. The mutagenic activity of pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and *Escherichia coli* strain WP2uvrA were treated with pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- in ethanol at concentrations up to 5000 µg/plate. No increases in the mean number of revertant colonies were observed at any tested concentration in the presence or absence of S9 (RIFM, 2017). Under the conditions of the study, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was not mutagenic in the Ames test.

The clastogenic activity of pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was evaluated in an *in vitro* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 487. Human peripheral blood lymphocytes were treated with pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- in dimethyl sulfoxide (DMSO) at concentrations up to 1940 µg/mL in the dose range finding (DRF) study; micronuclei analysis was conducted at concentrations up to 200 µg/mL in the presence and absence of metabolic activation. Pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- did not induce binucleated cells with micronuclei when tested up to the cytotoxic level concentration in either the presence or absence of an S9 activation system (RIFM, 2018). Under the conditions of the study, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was considered to be non-clastogenic in the *in vitro* micronucleus test (Dutta, 2018; Draft).

Based on the data available, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- does not present a concern for genotoxic potential.

Additional References: None

Literature Search and Risk Assessment Completed On: 03/10/23

11.1.2. Repeated dose toxicity

There are insufficient repeated dose toxicity data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- or any read-across materials. The total systemic exposure to pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is below the TTC for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

11.1.2.1. Risk assessment. There are no repeated dose toxicity data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- or any read-across materials that can be used to support the repeated dose toxicity endpoint. The total systemic exposure (0.15 µg/kg/day) is below the TTC for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- (1.5 µg/kg/day; Kroes et al., 2007).

Additional References: None

Literature Search and Risk Assessment Completed On: 02/23/23

11.1.3. Reproductive toxicity

There are insufficient reproductive toxicity data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- or any read-across materials. The total systemic exposure to pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is below the TTC for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

11.1.3.1. Risk assessment. There are no reproductive toxicity data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- or any read-across materials that can be used to support the reproductive toxicity endpoint. The total systemic exposure (0.15 µg/kg/day) is below the TTC for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- (1.5 µg/kg/day; Kroes et al., 2007; Laferriere et al., 2012).

Additional References: None

Literature Search and Risk Assessment Completed On: 02/23/23

11.1.4. Skin sensitization

Based on the application of DST, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- does not present a safety concern for skin sensitization under the current, declared levels of use.

11.1.4.1. Risk assessment. No skin sensitization studies are available for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- (Table 1).

Table 1
Summary of existing data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl].

WoE Skin Sensitization Potency Category ¹	Human Data				Animal Data		
	NOEL-CNIH (induction) µg/cm ²	NOEL-HMT (induction) µg/cm ²	LOEL (induction) µg/cm ²	WoE NESIL µg/cm ²	LLNA Weighted Mean EC3 Value µg/cm ²	GPMT	Buehler
	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Human potency category unknown; Current exposure level below the DST for reactive materials.	<i>In vitro</i> Data				<i>In silico</i> protein binding alerts (OECD Toolbox v4.5)		
	KE 1	KE 2	KE 3	Target Material	Autoxidation simulator	Metabolism simulator	
	N/A	N/A	N/A	No alert found	No alert found	No alert found	

NOEL = No observed effect level; CNIH = Confirmation of No Induction in Humans; HMT = Human Maximization Test; LOEL = lowest observed effect level; KE = Key Event; N/A = Not Available.

¹WoE Skin Sensitization Potency Category is only applicable for identified sensitizers with sufficient data, based on collective consideration of all available data (Na et al., 2021).

Table 2

Supported concentrations for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl] that present no appreciable risk for skin sensitization based on reactive DST.

IFRA Category ^a	Description of Product Type	Supported Concentrations ^b (%) in Finished Products Based on Reactive DST	Reported 95th Percentile Use Concentrations in Finished Products
1	Products applied to the lips	0.0049	NRU ^d
2	Products applied to the axillae	0.0015	0.0011
3	Products applied to the face using fingertips	0.029	2.8×10^{-4}
4	Fine fragrance products	0.027	0.020
5	Products applied to the face and body using the hands (palms), primarily leave-on	0.0070	6.3×10^{-4}
6	Products with oral and lip exposure	0.016	NRU ^d
7	Products applied to the hair with some hand contact	0.056	NRU ^d
8	Products with significant ano-genital exposure	0.0029	No Data ^c
9	Products with body and hand exposure, primarily rinse-off	0.054	8.1×10^{-4}
10	Household care products with mostly hand contact	0.19	2.0×10^{-4}
11	Products with intended skin contact but minimal transfer of fragrance to skin from inert substrate	0.11	No Data ^c
12	Products not intended for direct skin contact, minimal or insignificant transfer to skin	Not restricted	0.017

^a For a description of the categories, refer to the IFRA/RIFM Information Booklet.

^b These levels represent maximum acceptable concentrations based on the DST. However, additional studies may show it could be used at higher levels.

^c Fragrance exposure from these products is very low. These products are not currently in the Creme RIFM Aggregate Exposure Model.

^d No reported use.

Pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl] is predicted *in silico* to be non-reactive with skin proteins directly (Roberts et al., 2007; Toxtree v3.1.0; OECD Toolbox v4.5); however, this material was determined to be reactive to skin proteins by expert judgment. Acting conservatively, due to the lack of data, the reported exposure was benchmarked utilizing the reactive DST of $64 \mu\text{g}/\text{cm}^2$ (Safford, 2008; Safford et al., 2011; Roberts et al., 2015; Safford et al., 2015b). The current exposure from the 95th percentile concentration is below the DST for reactive materials when evaluated in all QRA categories. Table 2 provides the supported concentrations for 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl] that present no appreciable risk for skin sensitization based on the reactive DST. These levels represent supported concentrations based on the DST approach. However, additional studies may show it could be used at higher levels.

Additional References: None

Literature Search and Risk Assessment Completed On: 02/23/23

11.1.5. Photoirritation/photoallergenicity

Based on the available UV/Vis spectra for the structurally related material, pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7), pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- would not be expected to present a concern for photoirritation or photoallergenicity.

11.1.5.1. Risk assessment. There are no photoirritation studies available for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- in experimental models. UV/Vis absorption spectra were not available for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-. UV

absorption spectra on the structurally related material, pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7), indicate no absorption between 290 and 500 nm. The corresponding molar absorption coefficient is below the benchmark of concern for photoirritation and photoallergenicity (Henry et al., 2009). Based on the lack of absorbance for the structurally related analog pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-, pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- does not present a concern for photoirritation or photoallergenicity.

11.1.5.2. UV spectra analysis. UV/Vis absorption spectra were not available for the target material pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-. UV absorption spectra (OECD TG 101) were available for the structurally related read-across analog pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7). The spectra indicate no absorbance in the range of 290–500 nm. The molar absorption coefficient ($690 \text{ L mol}^{-1} \bullet \text{cm}^{-1}$) for the absorbance maximum is below the benchmark of concern for photoirritating or photoallergenic effects, $1000 \text{ L mol}^{-1} \bullet \text{cm}^{-1}$ (Henry et al., 2009).

Additional References: None

Literature Search and Risk Assessment Completed On: 03/07/23

11.1.6. Local Respiratory Toxicity

The margin of exposure could not be calculated due to the lack of appropriate data. The exposure level for pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- is below the Cramer Class III TTC value for inhalation exposure local effects.

	LC50 (Fish) (mg/L)	EC50 (Daphnia) (mg/L)	EC50 (Algae) (mg/L)	AF	PNEC ($\mu\text{g}/\text{L}$)	Chemical Class
RIFM Framework Screening-level (Tier 1)	7.50			1000000	0.00750	

11.1.6.1. Risk assessment. There are no inhalation data available on pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-. Based on the Creme RIFM Model, the inhalation exposure is 0.0017 mg/day. This exposure is 276.5 times lower than the Cramer Class III TTC value of 0.47 mg/day (based on human lung weight of 650 g; Carthew et al., 2009); therefore, the exposure at the current level of use is deemed safe.

Additional References: None

Literature Search and Risk Assessment Completed On: 03/08/23

11.2. Environmental endpoint summary

11.2.1. Screening-level assessment

A screening-level risk assessment of pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was performed following the RIFM Environmental Framework (Salvito et al., 2002), which provides 3 tiered levels of screening for aquatic risk. In Tier 1, only the material's regional VoU, its log K_{OW} , and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio of Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in Salvito et al. (2002). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model (US EPA, 2012b), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegradation and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA VoU Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- was identified as a fragrance material with no potential to present a possible risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1).

A screening-level hazard assessment using EPI Suite v4.11 (US EPA, 2012a) identified pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- as possibly being persistent but not bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent and bioaccumulative and toxic or very persistent and very bioaccumulative as defined in the Criteria Document (Api et al., 2015). As noted in the Criteria Document, the screening criteria applied are the same as those used in the EU for REACH (ECHA, 2017a). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF ≥ 2000 L/kg. Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11).

11.2.1.1. Risk assessment. Based on the current VoU (2019), pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- presents no risk to the aquatic compartment in the screening-level assessment.

11.2.1.2. Key studies. **Biodegradation:**

No data available.

Ecotoxicity:

No data available.

11.2.1.3. Other available data. Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- has not been registered for REACH.

11.2.2. Risk assessment refinement

Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in $\mu\text{g/L}$)

Endpoints used to calculate PNEC are underlined.

Exposure information and PEC calculation (following RIFM Environmental Framework: Salvito et al., 2002)

Exposure	Europe (EU)	North America (NA)
Log K_{OW} Used	3.75	3.75
Biodegradation Factor Used	0	0
Dilution Factor	3	3
Regional VoU Tonnage Band	<1	<1
Risk Characterization: PEC/PNEC	<1	<1

Based on available data, the RQ for this material is < 1. No further assessment is necessary.

The RIFM PNEC is 0.00750 $\mu\text{g/L}$. The revised PEC/PNECs for EU and NA are not applicable. The material was cleared at the screening-level; therefore, it does not present a risk to the aquatic environment at the current reported volumes of use.

Literature Search and Risk Assessment Completed On: 03/07/23

12. Literature Search*

- **RIFM Database:** Target, Fragrance Structure-Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <https://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox:** <https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm>
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubChem:** <https://pubchem.ncbi.nlm.nih.gov/>
- **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed>
- **National Library of Medicine Technical Bulletin:** https://www.nlm.nih.gov/pubs/techbull/nd19/nd19_toxnet_new_locations.html
- **IARC:** <https://monographs.iarc.fr>
- **OECD SIDS:** <https://hpvchemicals.oecd.org/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>
- **US EPA ChemView:** <https://chemview.epa.gov/chemview/>
- **Japanese NITE:** https://www.nite.go.jp/en/chem/chrip/chrip_search/systemTop
- **Japan Existing Chemical Data Base (JECDB):** http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus>

Search keywords: CAS number and/or material names

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. RIFM staff are employees of the Research Institute for Fragrance Materials, Inc. (RIFM). The Expert Panel receives a small honorarium for time spent reviewing the subject work.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fct.2023.114304>.

Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list. The links listed above were active as of 09/28/23.



Appendix

Read-across Justification:

Methods

The read-across analog was identified using RIFM fragrance chemicals inventory clustering and read-across search criteria (Date et al., 2020). These criteria are in compliance with the strategy for structuring and reporting a read-across prediction of toxicity as described in Schultz et al. (2015) and are consistent with the guidance provided by OECD within Integrated Approaches for Testing and Assessment (OECD, 2015) and the European Chemicals Agency read-across assessment framework (ECHA, 2017b).

- First, materials were clustered based on their structural similarity. Second, data availability and data quality on the selected cluster were examined. Third, appropriate read-across analogs from the cluster were confirmed by expert judgment.
- Tanimoto structure similarity scores were calculated using FCFC4 fingerprints (Rogers and Hahn, 2010).
- The physical–chemical properties of the target material and the read-across analogs were calculated using EPI Suite (US EPA, 2012a).
- J_{\max} values were calculated using RIFM's skin absorption model (SAM). The parameters were calculated using the consensus model (Shen et al., 2014).
- DNA binding, mutagenicity, genotoxicity alerts, and oncologic classification predictions were generated using OECD QSAR Toolbox v4.5 (OECD, 2021).
- ER binding and repeat dose categorization were generated using the OECD QSAR Toolbox v4.5 (OECD, 2021).
- Developmental toxicity was predicted using CAESAR v2.1.7 (Cassano et al., 2010), and skin sensitization was predicted using Toxtree v2.6.13.
- Protein binding was predicted using OECD QSAR Toolbox v4.5 (OECD, 2021).
- The major metabolites for the target material and read-across analogs were determined and evaluated using the OECD QSAR Toolbox v4.5 (OECD, 2021).
- To keep continuity and compatibility with *in silico* alerts, OECD QSAR Toolbox v4.5 was selected as the alert system.

	Target Material	Read-across Material
Principal Name	Pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-	Pyridine, 2-(2,4-dimethylcyclohexyl)-
CAS No.	862079-91-2	885702-72-7
Structure		
Similarity (Tanimoto Score)		0.34
SMILES	CC12CC(C=C1)C(C2)c1ccnc1	CC1CCC(C(C)C1)c1ccccn1
Endpoint		Photoirritation/photoallergenicity
Molecular Formula	C ₁₃ H ₁₅ N	C ₁₃ H ₁₉ N
Molecular Weight (g/mol)	185.27	189.302
Melting Point (°C, EPI Suite)	66.65	52.09
Boiling Point (°C, EPI Suite)	268.40	270.37
Vapor Pressure (Pa @ 25°C, EPI Suite)	5.57E-01	6.96E-01
UV Spectra	Not available	No absorbance between 290 and 700 nm; molar absorption coefficient is below the benchmark (1000 L mol ⁻¹ • cm ⁻¹)
Water Solubility (mg/L, @ 25°C, WSKOW v1.42 in EPI Suite)	6.50E+02	1.55E+02
Log K_{OW}	3.75	4.46
J_{max} (µg/cm²/h, SAM)	63.73	22.43
Henry's Law (Pa•m³/mol, Bond Method, EPI Suite)	9.80E-01	2.52E+00
Metabolism		
Rat Liver S9 Metabolism Simulator and Structural Alerts for Metabolites (OECD QSAR Toolbox v4.5)	See Supplemental Data 1	See Supplemental Data 2

Summary

There are insufficient toxicity data on pyridine, 4-[1(4,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- (CAS # 862079-91-2). Hence, *in silico* evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, physical–chemical properties,

and expert judgment, pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7) was identified as read-across analog with sufficient data for toxicological evaluation.

Conclusions

- Pyridine, 2-(2,4-dimethylcyclohexyl)- (CAS # 885702-72-7) was used as a read-across analog for the target material, pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]- (CAS # 862079-91-2), for the photoirritation/photoallergenicity endpoint.
 - o The target material and the read-across analog are structurally similar and belong to the group of aryl-substituted pyridines.
 - o The key difference between the target material and the read-across analog is that the target material has a pyridine substitution in the para position by an aryl ring with unsaturation. The read-across analog is a pyridine substituted in the ortho position by a saturated aryl ring. The read-across analog contains the structural features of the target material that are relevant to this endpoint and is expected to have equal or greater potential for toxicity as compared to the target.
 - o The similarity between the target material and the read-across analog is indicated by the Tanimoto score. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
 - o The physical–chemical properties of the target material and the read-across analog are sufficiently similar to enable a comparison of their toxicological properties.
 - o According to the OECD QSAR Toolbox v4.5, structural alerts for toxicological endpoints are consistent between the target material and the read-across analog.
 - o The target material and the read-across analog do not have a chromophore that is expected to absorb in the UV/Vis range of the electromagnetic spectrum, which is of interest to human health toxicity. The data on the read-across analog confirm that the substance does not absorb in the UV/Vis range. Therefore, the structural difference between the target material and the read-across analog is toxicologically insignificant for the photoirritation/photoallergy endpoint, and the target material can be predicted to not absorb in the UV/Vis range.
 - o The target material and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
 - o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.

References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the Research Institute for fragrance materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. *Food Chem. Toxicol.* 82, S1–S19.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food Chem. Toxicol.* 47 (6), 1287–1295.
- Cassano, A., Manganaro, A., Martin, T., Young, D., Piclin, N., Pintore, M., Bigoni, D., Benfenati, E., 2010. CAESAR models for developmental toxicity. *Chem. Cent. J.* (4 Suppl. 1), S4.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regul. Toxicol. Pharmacol.* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regul. Toxicol. Pharmacol.* 88, 144–156.
- Date, M.S., O'Brien, D., Botelho, D.J., Schultz, T.W., et al., 2020. Clustering a chemical inventory for safety assessment of fragrance ingredients: identifying read-across analogs to address data gaps. *Chem. Res. Toxicol.* 33 (7), 1709–1718, 2020.
- ECHA, 2017a. Guidance on Information Requirements and Chemical Safety Assessment: Chapter R.11: PBT Assessment. Retrieved from: <https://echa.europa.eu/en/web/guest/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- ECHA, 2017b. Read-across Assessment Framework (RAAF). Retrieved from: https://echa.europa.eu/documents/10162/13628/raaf_en.pdf/614e5d61-891d-4154-8a47-87efebd1851a.
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *J. Photochem. Photobiol. B Biol.* 96 (1), 57–62.
- IFRA (International Fragrance Association), 2019. Volume of Use Survey, January–December 2019.
- Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J.M., 2007. Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. *Food Chem. Toxicol.* 45 (12), 2533–2562.
- Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., et al., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. *Regul. Toxicol. Pharmacol.* 62 (1), 160–182.
- Na, M., Ritacco, G., O'Brien, D., Lavelle, M., Api, A., Basketter, D., 2021. Fragrance skin sensitization evaluation and human testing: 30-year experience. *Dermatitis* 32 (5), 339–352, 2021 Sep–Oct 01.
- OECD, 2015. *Guidance Document on the Reporting of Integrated Approaches to Testing and Assessment (IATA)*. ENV/JM/HA(2015)7. Retrieved from: [https://one.oecd.org/document/ENV/JM/HA\(2015\)7/en/pdf](https://one.oecd.org/document/ENV/JM/HA(2015)7/en/pdf).
- OECD, 2021. The OECD QSAR Toolbox, v3.2–4.5. Retrieved from: <http://www.qsartoolbox.org/>.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2017. Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-: Bacterial Reverse Mutation Assay. RIFM Report Number 73148. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2018. Pyridine, 4-[1(4-,5 or 6)-methylbicyclo[2.2.1]hept-5-en-2-yl]-: in Vitro Mammalian Cell Micronucleus Assay in Human Peripheral Blood Lymphocytes (HPBL). RIFM Report Number 79660. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2021. Exposure Survey 33. October 2021.
- Roberts, D.W., Api, A.M., Safford, R.J., Lalko, J.F., 2015. Principles for identification of high potency category chemicals for which the dermal sensitization threshold (DST) approach should not be applied. *Regul. Toxicol. Pharmacol.* 72 (3), 683–693.
- Roberts, D.W., Patlewicz, G., Kern, P.S., Gerberick, F., Kimber, I., Dearman, R.J., Ryan, C.A., Basketter, D.A., Aptula, A.O., 2007. Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization. *Chem. Res. Toxicol.* 20 (7), 1019–1030.
- Rogers, D., Hahn, M., 2010. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* 50 (5), 742–754.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015b. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regul. Toxicol. Pharmacol.* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regul. Toxicol. Pharmacol.* 86, 148–156.
- Safford, R.J., 2008. The dermal sensitisation threshold—A TTC approach for allergic contact dermatitis. *Regul. Toxicol. Pharmacol.* 51 (2), 195–200.
- Safford, R.J., Api, A.M., Roberts, D.W., Lalko, J.F., 2015a. Extension of the dermal sensitization threshold (DST) approach to incorporate chemicals classified as reactive. *Regul. Toxicol. Pharmacol.* 72 (3), 694–701.
- Safford, R.J., Aptula, A.O., Gilmour, N., 2011. Refinement of the dermal sensitisation threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains. *Regul. Toxicol. Pharmacol.* 60 (2), 218–224.
- Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance materials for aquatic risk assessment. *Environ. Toxicol. Chem.* 21 (6), 1301–1308.
- Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D.J., Mahony, C., Schwarz, M., White, A., Cronin, M.T., 2015. A strategy for structuring and reporting a read-across prediction of toxicity. *Regul. Toxicol. Pharmacol.* 72 (3), 586–601.
- Shen, J., Kromidas, L., Schultz, T., Bhatia, S., 2014. An *in silico* skin absorption model for fragrance materials. *Food Chem. Toxicol.* 74, 164–176.
- US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2012b. The ECOSAR (ECOLOGICAL Structure Activity Relationship) Class Program for Microsoft Windows, v2.0. United States Environmental Protection Agency, Washington, DC, USA.